Mapi Pharma Research site 12 — Washington D.C., District of Columbia

Mapi Pharma Research site 12 is a clinical research site located in Washington D.C., District of Columbia, United States 20007.

Crixeo Health Trust Score: 51/100 (POOR). This profile has not yet been claimed by the site owner.

Mapi Pharma Research site 12 has participated in 1 clinical trials.

Therapeutic areas: Multiple Sclerosis, Relapsing-Remitting.

Sponsors: Mapi Pharma Ltd..

Sponsor Feasibility Report

Trust Score: 51/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Mapi Pharma Research site 12?

Mapi Pharma Research site 12 has a Crixeo Trust Score of 51/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Mapi Pharma Research site 12 conducted?

Mapi Pharma Research site 12 has 1 clinical trials on record. Their work covers Multiple Sclerosis, Relapsing-Remitting.

Is Mapi Pharma Research site 12 accredited by Crixeo Health?

Mapi Pharma Research site 12 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Mapi Pharma Research site 12?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.